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A B S T R A C T
Background: Renin-angiotensin system inhibitors (ACEI/ARB-II), diuretics and NSAIDs, a 
combination known as “Triple Whammy”, can result in decreased glomerular filtration rate 
(GFR) and acute kidney injury (AKI).
Objectives: To describe the incidence of AKI for each drug type and their combinations. To 
define the profile of patients admitted for drug-related AKI secondary to Triple Whammy 
drugs (AKITW), with an assessment of costs and mortality.
Methods: A retrospective observational 15-month study developed in three stages:
-  First: a cross-sectional stage to identify and describe hospitalizations due to AKITW.
-  Second: a follow-up stage of an outpatient cohort consuming these drugs (15,307 subjects).
-  Third: a cohort stage to assess costs and mortality, which compared 62 hospitalized patients 
with AKITW and 62 without AKI, paired by medical specialty, sex, age and comorbidity 
according to their Clinical Risk Groups.
Results: There were 85 hospitalization episodes due to AKITW, and 78% of patients were over 
the age of 70. The incidence of AKITW in the population was 3.40 cases/1000 users/year 
(95% CI: 2.59–4.45). By categories, these were: NSAIDs + diuretics 8.99 (95% CI: 3.16–25.3); 
Triple Whammy 8.82 (95% CI: 4.4–17.3); ACEI/ARB-II + diuretics 6.87 (95% CI: 4.81–9.82); and 
monotherapy with diuretics 3.31 (95% CI: 1.39–7.85). Mean hospital stay was 7.6 days (SD 6.4), 
and mean avoidable costs were estimated at €214,604/100,000 inhabitants/year. Mortality 
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ducted in the Madrid Community. The 2002 study by L.M. Lou, 
et al.6, which was conducted at a Spanish district hospital 
with characteristics similar to ours, indicated that 79% of hos-
pitalizations due to AKI originated outside the hospital. The 
cause was volume depletion in 34.2% of cases, a datum that 
highlighted the elevated incidence of antihypertensive treat-
ments (primarily renin-angiotensin system inhibitors) and/
or diuretics as coadjuvant factors for AKI.
However, the study of drug-related acute kidney injury has 
received little attention in the literature; meanwhile, its impli-
cations in terms of increased mortality, days of hospitaliza-
Introduction
The combination of renin-angiotensin system inhibitor (ACEI 
or ARB-II) antihypertensive drugs with diuretics, which is 
often associated with analgesic treatments including non-ste-
roidal anti-inflammatory drugs (NSAIDs) in senior patients, 
may cause acute kidney injury (AKI). These drug interactions 
have not been well studied in the literature.1-4
In 1996, the incidence of AKI in Spain was 209 cases/mil-
lion adults/year5 according to a study by Liaño, et al., con-
Palabras clave: 
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during hospitalization and at 12 months was 11.3% and 38.7% respectively, and there were 
no significant differences when compared with the control group.
Conclusions: Treatment with ACEI, ARB-II, diuretics and/or NSAIDs shows a high incidence of 
hospitalization episodes due to AKI; diuretics as monotherapy or dual and triple combination 
therapy cause the highest incidence. AKITW involves high health care costs and avoidable 
mortality.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Fracaso renal agudo secundario a combinación de inhibidores del 
sistema renina-angiotensina, diuréticos y AINES. “La Triple Whammy”
R E S U M E N
Introducción: Inhibidores del sistema renina-angiotensina (IECAS/ARA II), diuréticos y AINES, 
combinación conocida como “Triple Whammy”, pueden producir descenso de filtrado 
glomerular y fracaso renal agudo (FRA).
Objetivos: Describir la incidencia de FRA para cada tipo de fármaco y sus combinaciones. 
Caracterizar el perfil de paciente que ingresa por FRA extrahospitalario secundario a fármacos 
de la Triple Whammy (FRAETW), evaluando costes y mortalidad.
Métodos: estudio observacional retrospectivo realizado durante 15 meses y desarrollado en 
tres etapas: 
- 1º Etapa transversal de identificación y descripción de los ingresos hospitalarios por FRAETW.
-  2º Etapa de seguimiento de una cohorte ambulatoria consumidora de estos fármacos 
(15.307 consumidores)
-  3º Etapa de cohortes para evaluar costes y mortalidad, contrastando 62 pacientes ingresados 
con FRAETW, con 62 pacientes sin FRA, apareados por especialidad médica, sexo, edad y 
comorbilidad según Clinical Risk Groups. 
Resultados: 85 ingresos por FRAETW, 78% mayores de 70 años. Incidencia poblacional de 
FRAETW: 3,40 casos/1.000 consumidores/año (IC95% 2,59-4,45). Por categorías: AINES + 
diuréticos 8,99(IC95% 3,16-25,3), la “Triple Whammy” 8,82(IC 95% 4,4-17,3), IECA/ARA II + 
diuréticos 6,87(IC95% 4,81-9,82) y la monoterapia con diuréticos 3,31(IC95% 1,39-7,85). Estancia 
media 7,6 días (DE 6,4), estimándose coste medio evitable de 214.604 €/100.000 habitantes/
año. Mortalidad del 11,3% durante el ingreso y del 38,7% a los 12 meses, sin diferencias 
significativas con los controles. 
Conclusiones: El tratamiento con IECA, ARA II, diuréticos y/o AINES presenta elevada incidencia 
de ingreso por FRA, siendo los diuréticos en monoterapia, doble y triple terapia combinada 
los que ocasionan la mayor incidencia. El FRAETW supone elevados costes sanitarios y 
muertes evitables.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0).
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[Baix Empordà Comprehensive Health Service] Clinical 
Research Committee. Given the study methodology, which 
was based on a retrospective review of clinical-administrative 
records, informed consent was not requested. Data collection 
was performed by an authorized SSIBE professional and data 
were managed anonymously.
Design and patients
First stage of the study: A cross-sectional analysis was made of 
the 8,029 hospital admissions in the study period (January 
2011 to March 2012) in order to identify drug-related AKI cases 
secondary to ACEI/ARB-II, diuretics and/or NSAIDs, and to 
describe the clinical characteristics of the admitted patients 
and their previous medications. Drug-related acute kidney 
injury secondary to the use of Triple Whammy drugs (AKITW) 
was defined as hospital admission with a discharge code of 
AKI (ICD-9-CM 584.9) in a patient who had been receiving any 
of those drugs prior to admission and where, following an 
audit of the medical record by a nephrologist, the possible 
cause of AKI is attributed to the use of ACEI/ARB-II, diuretics 
and/or NSAIDs, either alone or in combination (a prerenal sit-
uation may be involved based on the presence of fever, vom-
iting or diarrhea). In addition, the patient’s baseline creatinine 
tion and costs are unknown. In 2000, MC Thomas7 coined the 
term “Triple Whammy” (TW) to refer to the adverse effects 
resulting from the combination of ACEI or ARB-II, diuretics 
and NSAIDs, particularly in seniors. Chertow, et al.8, observed 
that small creatinine increments of 0.3 or 0.4 mg/dL were 
associated with increased mortality, mean hospitalization 
days, and higher costs.
The objectives of our study were to describe the population 
prevalence of consumption and the incidence of outpatient 
AKI secondary to Triple Whammy drugs (AKITW): ACEI, 
ARB-II, diuretics and NSAIDs for each type of drug and their 
combinations, characterizing the profile of the admitted 
patients and analysing their mean hospital stay, hospital 
costs and mortality.
Methods
A retrospective observational study was conducted in three 
stages, with a mixed design, at Palamós Hospital (Baix 
Empordà district hospital), which is a reference hospital for 
127,151 inhabitants with 130 beds (Figure 1).
The study project complied with the principles of the 
World Medical Association Declaration of Helsinki and was 
approved by the Serveis de Salut Integrats Baix Empordà (SSIBE) 
Figure 1 – Study schedule. (a) Drugs according to ATC classification (NSAIDs not including ASA 100-300 mg, paracetamol or 
metamizole). (b) AKI associated with the use of ACEI/ARB-II/Diuretics/NSAIDs. (c) Randomized sample of controls paired by 
specialty, sex, age and comorbidity according to the Clinical Risk Groups (CRG). AKI: Acute kidney injury; ACEI: Angiotensin 
converting enzyme inhibitors; ARB II: Angiotensin-II receptor blockers; NSAID: Non-steroidal anti-inflammatory drugs.
Population living in Baix Empordà, 2011: 127,151 people
Stage 1
Stage 13
Palamós Hospital Discharge File including 
costs, 2011 (12 months)
Pairing
(º)
Patients admitted 
without AKI
62
Patients 
admitted with
drug-related
AKIb
62
Stage 2
Patients admitted with 
drug-related
AKIb
85
Population using 
ACEI/ARB-II/diuretics/NSAIDsa
15.307
 Population with drug-related AKIb,
January 2011–March 2012 (15 months)
65
Computerized pharmaceutical prescriptions
February 2011 (15 months)
Population assigned to health areas with prescription-related 
information: 87,160 
(February 2011)
Population admitted to Palamós Hospital: 8,029
Community-acquired AKI: 368
(January 2011–March 2012)
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post-dialysis sequela (considered as patients with ICD-9 code: 
585 who did not have CKD before admission), creatinine (base-
line, peak on admission, on discharge and at six months fol-
lowing admission), albuminemia on admission, K on 
admission, hospital stay (days), death (date). Renal function 
was measured with creatinine analyzed by Jaffe’s method, 
alkaline picrate and kinetic reading; traceability was guaran-
teed with the isotopic dilution mass spectrometry (IDMS). 
Glomerular filtration (GF) was calculated with MDRD4 IDMS.
Exacerbated CKD was considered as a patient previously 
diagnosed with CKD who had a creatinine level of more than 
0.3 mg/dL over their baseline creatinine value, which had 
been measured at least one month before admission. 
The pharmacy data of the population were obtained from 
the computerized prescription files of the primary health care 
services. Drugs of interest were classified by groups based on 
ATC codes (World Health Organizat ion Anatomical, 
Therapeutic, Chemical classification system): ACEI, ARB-II, 
diuretics and NSAIDs (not including acetylsalicylic acid 100-
300 mg, paracetamol or metamizole). The ACEI and ARB-II 
groups were considered a single drug type because of their 
similar mechanism of action. The use of one, two or three 
diuretics and NSAIDs were considered separately. Drugs pre-
scribed during hospitalization were not considered.
Data for hospitalization costs, which are calculated yearly 
with the full-costing system, were obtained from the Serveis 
de Salut Integrats (SSIBE) costs file. This system follows the 
methodology and recommendations from the analytical 
accounting workgroup of the Servei Català de la Salut [Catalan 
Health Service] Central Financial Office11,12 and the Red 
Española de Costes Hospitalarios (RECH) [Spanish Hospital Costs 
Network]13,14. The cost associated with each hospitalization 
episode was calculated individually using the clinical and 
activity information recorded from admission to discharge. 
Thus, the cost of each hospitalization episode was obtained 
based on the number of hospitalization days, minutes in the 
operating room, dialysis sessions, single medication doses, 
laboratory tests, imaging tests and other tests performed 
from admission to discharge. In the 2011 fiscal year, the mean 
hospital stay cost at Palamós Hospital was €279.63, one min-
ute in the operating room was €10.39 and each dialysis ses-
sion was €146.45. The cost of single medication doses was 
assigned directly to the episode at the weighted mean price. 
Finally, the costs for laboratory tests, diagnostic imaging tests 
and the remaining tests was input according to the mean cost 
of each technique performed based on each department’s 
catalogue of services.
Statistical analysis
In order to identify the hospitalizations due to AKITW in asso-
ciation with these drugs, we conducted a univariate statisti-
cal analysis with frequency, mean and standard deviation, 
according to the characteristics of each variable. 
Drug combinations were analyzed as exclusive categories. 
To measure the impact of drug use, the population incidence 
was measured for each category with its 95% confidence inter-
val. 
value was 1.3 mg/dL or lower at least one month before admis-
sion, which increased to more than 1.4 mg/dL on admission.
Excluded from the study were cases of hospital-acquired 
AKI (defined as patients who are admitted with a creatinine 
value below 1.3 mg/dL that increases to more than 1.4 mg/dL 
during hospitalization), obstructive AKI, glomerulonephritis, 
hepatorenal syndrome, decompensated heart failure, multiple 
organ failure, infection, ischemia, poisoning, end-stage can-
cer, exposure to radiocontrast agents or known nephrotoxic 
drugs, and multifactorial cases
Second stage of the study: Four basic health care areas (BHA) 
share an information system of computerized medical files 
with our hospital. As the prescription records of the 87,160 
patients belonging to the BHA were available to us, we fol-
lowed up a cohort of the 15,307 outpatients who had been 
prescribed one or more ACEI/ARB-II, diuretics or NSAIDs in 
February 2011. Our goal was to analyze the prevalence of use 
and incidence of drug-related AKI of this population for each 
type of drug and their combinations. The data from this 
cohort were cross-referenced with the data from hospital 
admissions due to AKITW that had been identified in the first 
stage. Out of the 85 cases of AKITW detected in stage 1 (15 
months of follow-up), we selected the 65 cases belonging to 
the population of the four BHA with available computerized 
medical records and drug prescription data. 
Third stage of the study: A cohort study was used to assess 
the impact of AKITW on hospital stays, costs and mortality. 
The study population was limited to hospitalization episodes 
in 2011 (12 months) of residents of the four BHA for whom 
prescription data pharmacy costs were available. All the hos-
pitalization episodes due to AKITW belonging to the 4 BHA 
were considered cases (62 patients). The control group was 
made up of 62 randomly selected hospital admissions of 
patients without AKI, paired by medical specialty, sex, age 
and comorbidities according to Clinical Risk Group (CRG).9,10
Variables and data sources
Data for the selection and analysis of the hospitalizations 
were obtained from the Palamós Hospital computerized hos-
pital admission files. The medical records were reviewed 
thoroughly by a nephrologist, who compiled detailed infor-
mation about patient characteristics and progression. The 
variables collected on hospitalization episodes for AKITW 
were: age, sex, use of ACEI/ARB-II, diuretics and NSAIDs 
before admission except for ASA 100-300 mg (drug, mean daily 
dose and treatment duration in weeks), history of hyperten-
sion (HTN) (defined by antihypertensive medication use), 
chronic kidney disease (CKD) prior to admission (defined as 
any patient admitted under code ICD-9: 585), chronic heart 
failure (CHF) (defined as any patient admitted under code ICD-
9: 428), prior rheumatic disease (previous diagnosis of rheu-
matic disease with follow-up by a rheumatologist), associated 
prerenal cause (depletion due to fever, vomiting or diarrhea), 
signs of dehydration (admitting physician recorded dehydra-
tion on the ER report, or patient was admitted with hypoten-
sion and the examination revealed dry skin or mucosae), 
edema, pain and cause of pain, need for dialysis, CKD as a 
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The mean baseline creatinine value prior to admission was 
1.32 mg/dL (SD 0.50) and the mean creatinine increase from 
baseline to admission was 1.77 mg/dL (SD 1.51). In 34% of 
patients, peak creatinine doubled baseline creatinine levels. 
Six months after discharge, mean creatinine had an increase 
of 13.89% from the pre-admission baseline creatinine. The 
mean baseline GFR was 57.3 mL/min/1.73m2, and at six 
months it was 52.77 mL/min/1.73 m2, which was a decrease 
of 4.6%.
More than half the patients had hypoalbuminemia, which 
was serious (< 2.5 g/dL) in 19% of cases. One-third were admit-
ted with hyperkalemia, and three cases were serious enough 
to cause death after admission. One patient required dialysis 
and more than 10% of patients had CKD as a sequela for six 
months after admission. 
With respect to the drugs the patients were taking before 
admission, ACEI prescriptions were identified in half of cases; 
three-quarters of these patients had been taking them for 
more than four weeks. The most widely used ACEI was enal-
april, which was consumed by three out of four ACEI users. 
One-third of patients were ARB-II users, most of whom had 
been on treatment for more than four weeks. The most widely 
used form was losartan, which was being taken by a third of 
ARB-II users. Diuretics were prescribed in almost nine out of 
ten cases to treat the following: HTN in 55.4% of cases, CHF 
in 33.8%, and edema in 6%. Almost three-quarters of patients 
had been on treatment for more than four weeks and almost 
one-quarter had been prescribed more than one type of 
diuretic. The most widely used diuretic was furosemide, fol-
lowed by hydrochlorothiazide. NSAIDs were prescribed in just 
over one-fifth of cases; two-thirds of them had been on treat-
ment for more than four weeks. The most widely used NSAID 
was ibuprofen (Table 2).
Out of patients the admitted, 88.2% were on dual or triple 
therapy: 54% dual therapy, 39% combined ACEI/ARB-II + 
diuretics, and 34% Triple Whammy.
2.  Second stage of the study: Use of ACEI/ARB-II, diuretics and 
NSAIDs in the population and associated AKI
From a population of 87,160 people, a total of 15,307 were on 
the target drugs, which represented 175.62 users/1,000 inhab-
itants (Figure 1).
The population prevalence of use for each type of drug 
(alone and in various possible combinations among them) is 
shown in Figure 2. The most common type of use in the study 
population was monotherapy, which accounted for more than 
half of these users. The most common monotherapy was 
ACEI/ARB-II, and the least used were diuretics. More than one-
third of these users were on dual therapy, the most frequent 
being ACEI/ARB-II + diuretics. Just over 1 person per 100 
inhabitants had been prescribed the Triple Whammy.
Table 3 shows the incidence of AKI associated with ACEI/
ARB-II, diuretics and NSAIDs in the population consuming 
these drugs. Overall incidence was 3.40 cases/year/1,000 
users, which generally increased with the number of drugs 
combined. In monotherapy, the diuretics group had a relevant 
incidence, which increased when they were combined with 
To compare groups in the case-control analysis, a bivariate 
statistical analysis was conducted with Student’s t-test or chi-
square test, depending on the variable’s characteristics. 
Fisher’s exact test was used when applicable. P < 0.05 was 
considered statistically significant. The IBM SPSS Statistics 
20.0 program was used.
Results
1.  First stage of the study: Identification and characterization 
of drug-related AKI
Out of the 8,029 hospital admissions during the study period, 
415 cases of AKI were identified, of which 368 were drug-re-
lated AKI and 85 were attributed directly to the use of ACEI/
ARB-II, diuretics and/or NSAIDs (AKITW) (Figure 1). 
These 85 cases had a similar distribution between both 
sexes and mean age was 78.72 years (SD 11.69). When ana-
lyzed by age groups, the case distribution clearly shifted to 
the older age ranges (Table 1).
Practically half of the cases had a history of CKD or CHF 
prior to admission. In two-thirds of cases, there was a prere-
nal cause associated with ACEI/ARB-II, diuretics and/or 
NSAIDs (history of fever, vomiting or diarrhea in the days 
before admission). In four out of five cases, the medical 
records did not specify a cause of pain justifying the chronic 
use of NSAIDs; in 59% of cases where the cause was specified, 
it was chronic joint pain.
Table 1 – Clinical characteristics of hospitalization 
episodes due to acute kidney injury associated with 
ACEI, ARB-II, diuretics and/or NSAIDs (Hospital de 
Palamós, January 2011–March 2012)
Frequency 
(n = 85)
Valid 
percentage 
Drug-related prerenal cause 74 87.1%
Male sex 46 54.1%
Age (years)
40-49 3 3.5%
50-59 4 4.7%
60-69 12 14.1%
70-79 15 17.6%
80-89 38 44.7%
90 or older 13 15.3%
CKD prior to admission 39 45.9%
CHF prior to admission 38 44.7%
High blood pressure prior to admission 49 57.6%
Previous rheumatologic disease 9 10.6%
Concurrent disease  
(fever or vomiting or diarrhoea)
57 67.1%
Oedemas 15 18.0%
17 20.0%
Hyperkalaemia (K > 5.5 mEq/L) 29 34.1%
Hypoalbuminemia (albumin < 2.9 g/dL) 35 51.5%
Need for dialysis 1 1.2%
CKD as post-admission sequela 9 10.6%
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Table 2 – Drugs associated with drug-related acute kidney injury: types, dose and time of exposure 
(Palamós Hospital, January 2011–March 2012)
Drug type Frequency (n = 85) % valid Mean dose (mg/day) Standard deviation 
ACEIs 43 (50.6%)
Captopril 1 2.3% 50.0 0.0
Enalapril 33 76.7% 17.4 6.7
Fosinopril 1 2.3% 20.0 0.0
Lisinopril 2 4.7% 40.0 28.3
Perindopril 2 4.7% 5.0 0.0
Ramipril 4 9.3% 5.0 1.5
Weeks with ACEIs        
< 1 1 2.3%    
1-4 1 2.3%    
> 4 33 76.7%    
Unknown 8 18.6%    
ARB-II 28 (34.1%)      
Candesartan 4 14.3% 10.7 4.6
Irbesartan 2 7.1% 225.0 106.0
Losartan 9 32.1% 77.8 26.3
Olmesartan 3 10.7% 40.0 0.0
Telmisartan 3 10.7% 53.3 23.1
Valsartan 7 25.0% 182.9 60.4
Weeks with ARB-II
> 4 25 89.3%
Unknown 3 10.7%
Diuretics b 74 (87.1%) 
Espironolactona 13 17.6% 51.9 34.5
Furosemida 38 51.4% 53.2 24.8
Hidroclorotiazida 29 39.2% 21.4 14.4
Indapamida 2 2.7% 1.5 10.7
Torasemida 8 10.8% 7.5 2.6
Others 2 2.7%    
Number of diuretics combined        
1 57 77.0%    
2 16 21.6%    
3 1 1.4%    
Weeks with diuretics        
< 1 3 4.1%    
1-4 4 5.4%    
> 4 54 73.0%    
Unknown 13 17.6%    
AINEb 18 (21.2%)      
Diclofenaco 4 22.2% 137.5 25.0
Ibuprofeno 7 38.9% 1375.0 570.0
Indometacina 3 16.7% 75.0 50.0
Ketoprofeno 4 22.2% 50.0 28.8
Naproxeno 2 11.1% 1100.0 0.0
Number of NSAIDs combined        
1 16 88.9%    
2 2 11.1%    
Weeks with NSAIDs        
< 1 1 5.6%    
1-4 2 11.1%    
> 4 12 66.7%    
Unknown 3 16.7%    
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Regarding costs, the mean cost was €3,016 (SD 2,468) for 
cases and €2,663 (SD 2,876) for controls, with no significant 
differences between them (p = 0.43). When we consider that 
the total one-year cost was €187,049 for 87,160 inhabitants, we 
can estimate an annual avoidable cost of €214,604/100,000 
inhabitants/year.
Mortality was 11.3% for cases and 6.5% for controls during 
hospitalization and 40.3% and 38.7%, respectively, during the 
12-month follow-up. No statistically significant differences 
were found between the groups at those time points or during 
the follow-up at three, six and nine months (Figure 3).
Discussion
Our results suggest that the consumers of these drugs have 
an elevated incidence of AKI. Greater incidence was observed 
ACEI/ARB-II or NSAIDs in a dual therapy. In contrast, the inci-
dence of AKI associated with ACEI/ARB-II and NSAIDs, alone 
or combined among them, was lower. The incidence of asso-
ciated AKI in Triple Whammy users was similar to that of 
users of dual therapies that included diuretics.
3.  Third stage of the study: Impact of AKI associated with ACEI/
ARB-II, diuretics and/or NSAIDs
In the comparison of the AKITW cases with paired non-AKI 
controls, no statistically significant differences were found 
for mean hospital stay between the two groups: 7.6 days (SD 
6.4) for cases and 5.8 (SD 4.5) for controls (p = 0.07). The total 
number of hospital stays generated in one year due to AKI 
secondary to the target drugs was 473 days for 87,160 inhab-
itants. This represents an estimated 543 days of avoidable 
hospital stay/100,000 inhabitants/year.
Tabl3 3 – Use of ACEI/ARB-II, diuretics and NSAIDs in the overall population and associated acute kidney injury 
(Baix Empordà, January 2011–March 2012) 
Type of drug used by the overall 
population (exclusive categories) 
Usersa AKF cases, 15 
monthsa
AKF cases/year 
(estimation)
 % cases of AKF AKF 
incidence/1,000 
users/year
95% CI
ACEIs/ARB-II 4,264 4 3.2 6.20 0.75 0.26-2.14
Diuretics 1,451 6 4.8 9.20 3.31 1.39-7.85
NSAIDs b 3,286 1 0.8 1.50 0.24 0.04-1.62
ACEIs/ARB-II + diuretics 4,306 37 29.6 56.90 6.87 4.81-9.82
ACEIs/ARB-II + NSAIDs b 737 3 2.4 4.60 3.26 0.99-10.68
NSAIDsb + diuretics 356 4 3.2 6.20 8.99 3.16-25.30
ACEIs/ARB-II + diuretics + NSAIDs b 907 10 8.0 15.40 8.82 4.48-17.31
Total 15,307 65 52.0 100.00 3.40 2.59-4.45
0 10
6.5
11.3
27.4
29
30.6
30.6
35.5
35.5
40.3
38.7
20 30 40 50
Control group
Acute kidney failure
secondary to TW therapy
Mortality (%)
On admission
Cumulative 3 m
Cumulative 6 m
Cumulative 9 m
Cumulative 12 m
Figure 3 – Mortality for AKI secondary to ACEI/ARB-II, 
diuretics and NSAIDs compared to admission of patients 
with no AKI (Palamós Hospital, 2011). (a) Control group: 
Hospitalizations of patients with no acute kidney injury 
paired by sex, age and comorbidity according to Clinical 
Risk Group (CRG) categories. All comparisons were non-
significant (p > 0.05 based on Fischer’s exact test). TW: 
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chronic diuretic treatment (more than four weeks) and 21.6% 
were on two diuretics combined. 
These were patients with decreased baseline GF, in many 
cases with a history of CKD or CHF, who were treated with 
diuretics, primarily for hypertension. They generally had mild 
or moderate AKI, with small creatinine increases that were 
resolved with hydration in most cases. Nevertheless, 10% of 
patients had CKD as a sequela and three patients died of 
hyperkalemia during admission. In four of five cases, the 
patients’ medical records did not specify a cause of pain jus-
tifying the chronic use of NSAIDs, and in 59% of cases where 
the cause was specified, it was chronic joint pain. These data 
reflect that NSAID therapies are started at times of acute pain 
and are not properly withdrawn afterwards.
The 2012 KDIGO guidelines17 already recommended start-
ing treatment with ACEI and ARB-II at low doses in patients 
with GFR < 45 mL/min and discontinue it temporarily in cases 
with concurrent disease. As for NSAIDs, the recommendation 
is to avoid their use in patients treated with renin-angiotensin 
system inhibitors, and prolonged therapies are not recom-
mended if GFR is < 60 mL/min. 
The STOPP/START18 criteria determine that prescribing 
diuretics for isolated ankle edema is inappropriate in patients 
older than 65 years because there is no evidence of their effi-
cacy. They are also not recommended as first-line monother-
apy in hypertension. NSAIDs should be avoided in moderate 
to severe hypertension and CHF, and their use for more than 
three months to relieve mild joint pain should be avoided. In 
cases of CKD, they are not recommended either.
Even though NSAIDs are not formally contraindicated in 
the elderly, they are a high-risk population for adverse effects, 
particularly AKI, and their use should be the result of a thor-
ough risk-benefit assessment. 
Only 58% of physicians noticed evident signs of dehydra-
tion on admission. Therefore, it is advisable that, in case of a 
concurrent condition, treatment with at least one of the target 
drugs be discontinued. This should be applied primarily to 
diuretics, even if the physician does not notice signs of dehy-
dration. When initiating these combinations, renal function 
and creatinine values are to be monitored.19 
The Fournier, et al.20 group from Toulouse has recently 
performed a new analysis of the review they conducted on 
their pharmacovigilance database of adverse pharmacolog-
ical effects in 2012. Their aim was to study whether NSAID 
half-life had an impact on the possibility of developing AKI. 
An association was found, not with the drugs’ half-life, but 
with the number of associated drugs, which coincided with 
the findings in previous publications and with our results. In 
our case, due to the small size of our sample, it was impos-
sible to analyze incidence differences based on the drugs’ 
half-lives.
A cost of €214,604/100,000 inhabitants/year for hospital-
ization episodes derived from a combined prescription of 
these drugs is a significant economic problem and, evidently, 
the three deaths that occurred during admission due to 
hyperkalemia could have been avoided with correct prescrip-
tion. 
Our study is not limited to the utilization of large databases. 
It is focused on drug-related AKI in conjunction with the audit-
for diuretics, as monotherapy or in dual or triple therapy; the 
highest incidence was for the dual therapy of diuretics + 
NSAIDs. Triple Whammy (ACEI/ARB-II + diuretics + NSAIDs) 
users had an AKI incidence similar to those taking dual ther-
apies that included diuretics. The main reason for the pre-
scription of diuretics in our patients was high blood pressure. 
Out of all the patients admitted due to AKITW, 87% used 
diuretics, 84.6% used ACEI/ARB-II and 38.5% used NSAIDs. In 
the population who had been prescribed one of these drugs, 
7.2% were on dual or triple therapy.
Similarly to Loboz et al.2, we observed that 54% of our 
admitted patients were on dual therapy, of which almost 40% 
were prescribed the ACEI/ARB-II + diuretics combination. 
Loboz et al.2 noticed that an increase in the dose of diuretics 
was related to a decrease in GFR and, for the remaining drugs, 
the risk was present even at low doses. Likewise, in our case, 
patients were consuming therapeutic or even low doses of 
diuretics and other drugs. This suggests that administering 
small doses of these drugs in combination fails to reduce the 
risk of AKI. Lou LM et al.6 and Huerta et al.15 also observed an 
increase in AKI incidence with the combination of ACEI and 
diuretics.
The association of ACEI/ARB-II + NSAIDs presented an ele-
vated incidence, although with a very broad confidence inter-
val, probably due to the limited number of cases.
Huerta et al.15 did not find an increased risk for the com-
bination of NSAIDs with renin-angiotensin system inhibitors.
Our data differ from the data found by Lapi et al.16, who 
found no risk for AKI when using dual therapy with diuretics 
or ACEI/ARB-II + NSAIDs. They only found a risk for AKI with 
the Triple Whammy, which was particularly noticeable in the 
first 30 days of treatment. In our study, we have seen that the 
hospitalized patients had been receiving treatment for more 
than four weeks, regardless of the drug group, and the trig-
gering factor for AKI had been a concurrent disease causing 
hypovolemia.
The profile of a patient at risk of suffering AKI with these 
drugs is an elderly patient with multiple conditions and on 
multiple concomitant medicantions. This risk exists even 
with drugs at low therapeutic doses. The presence of hypoal-
buminemia < 3 g/dL is alarming in 51% of hospitalization epi-
sodes due to AKITW, of which 19% were severe cases (< 2.5 g/
dL). This fact reflects the degree of malnutrition in a large 
part of the elderly population despite living at home. In 67% 
of cases, there was a triggering factor for AKI, such as fever, 
vomiting or diarrhea, in previous days. What probably makes 
the glomerular filtration drop abruptly is a concurrent disease 
causing volume depletion or, simply, an increase in baseline 
metabolism in a patient with intraglomerular pressure 
decreased by vasodilated efferent arterioles secondary to 
treatment with ACEI or ARB-II, combined with a circulating 
volume reduced by diuretics. Elderly patients are known to 
maintain their GF thanks to a complex system of intraglomer-
ular resistance. Due to the vessel rigidity present in these 
patients, the kidneys find it hard to adapt to changes in intra-
glomerular pressure and, therefore, are very sensitive to vol-
ume changes. This seems to suggest that the cause of the AKI 
was not the treatment with these drugs, but the onset of a 
concurrent disease. Of the admitted patients, 74% were on 
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ing of medical records by a nephrologist to ensure that the 
AKITW included in this study are only due to the treatment 
with these drugs, either alone or combined, without the con-
tribution of any other factor except for the prerenal situations 
discussed above. This avoids confusion due to the high mor-
tality associated with AKI for other causes. Most of the studies 
conducted so far are based on the utilization of large databases 
focused on overall AKI treatment. We analyzed the clinical 
patient characteristics to create a profile of at-risk patients, and 
we quantified the personal (mortality) and economic costs of 
AKI caused by incorrect drug combinations. 
The limitations of our study are the small number of cases 
and not having included treatment with ASA at low doses 
(100 and 300 mg) as an NSAID but instead as antiplatelet 
drug, as indicated in the pharmaceutical coding, since a large 
part of the patients admitted (19) were receiving prophylac-
tic treatment at these doses. Paracetamol at doses greater 
than 4 g/d could also have an NSAID effect. Both Paracetamol 
and the remaining NSAIDs are over-the-counter drugs in our 
pharmacies (our data only include NSAIDs prescribed by 
their physicians), so the use of NSAIDs could be underesti-
mated. We have also not analyzed the impact of impaired 
renal function cases that do not require admission. 
Therefore, the true incidence of AKITW may be higher and 
may also be generating elevated expenditures in the outpa-
tient setting. 
Conclusion
Diuretics in monotherapy, dual and triple combination ther-
apy (Triple Whammy) have an elevated incidence of AKI. Dual 
therapies including diuretics show the same incidence of AKI 
as the Triple Whammy. The profile of the at-risk patient is an 
elderly patient with an underlying renal or cardiac disease. 
The problem does not seem to be the drug itself but the onset 
of a concurrent disease causing hypovolemia. Monitoring 
renal function and potassium levels is recommended when 
these therapies are initiated and in situations of concurrent 
disease, following the recommendations from scientific soci-
eties (KDIGO and STOPP-START criteria).
In cases of concurrent disease, the temporary discontinua-
tion of the Triple Whammy drugs, particularly diuretics, is 
recommended. The use of NSAIDs should be minimized and 
treatment with diuretics should be monitored following hos-
pital discharge. Patient treatment should be adjusted to the 
situation at hand, with special attention given to people over 
the age of 80 who have concurrent conditions. AKI derived from 
a combination of Triple Whammy drugs has demonstrated high 
health care-related expenditures and avoidable deaths. Health 
care authorities should be aware of this serious issue and limit 
the over-the-counter availability of NSAIDs at pharmacies. 
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